{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-265711","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.848950+00:00","generated_at":"2026-05-17T00:17:33.458056+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Viridian closes $289M equity, $300M royalty financing; BLA submitted for veligrotug in TED","bullets":["Cash position ~$887.9M as of Oct 31, 2025, up from $490.9M at Sep 30, after equity, royalty, and debt financings.","BLA for veligrotug (IV) in thyroid eye disease submitted to FDA Oct 2025 with Priority Review request; mid-2026 launch targeted if approved.","Subcutaneous VRDN-003 topline data accelerated: REVEAL-1 in Q1 2026, REVEAL-2 in Q2 2026; both trials exceeded enrollment targets (132 and 204 patients).","R&D expenses $86.3M in Q3 2025 (up 25% YoY) driven by Ph3 programs; G&A $24.3M (up 69% YoY) from launch prep.","VRDN-006 showed IgG reduction proof-of-concept in Ph1; VRDN-008 IND on track for year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-265711","json":"https://secwatch.observer/filing/0001193125-25-265711.json","markdown":"https://secwatch.observer/filing/0001193125-25-265711.md","text":"https://secwatch.observer/filing/0001193125-25-265711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/0001193125-25-265711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/d33707d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:17:33.458056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}